SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg11/16/2007 10:48:32 AM
  Read Replies (1) of 3044
 
CHMP Adopts Negative Opinion on Appeal on European Application For natalizumab for the Treatment of Crohn's Disease
Friday November 16, 9:57 am ET

[Unclear to me if this is to be considered positive or negative from MLNM's point of view. Dunsire recently has started to talk much more about MLN0002 indicating that the drug has advanced its position in the PR-order. Natalizumab is of course a much more complicated mAb with its use for both UC-like indications as well as for multiple sclerosis].

DUBLIN, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN - News) and Biogen Idec (NASDAQ: BIIB - News) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion on the marketing authorization for natalizumab as a treatment for Crohn's disease. This decision is on the appeal the companies filed following a previous negative opinion adopted by the CHMP earlier in 2007.

This negative opinion is now referred to the European Commission (EC), which grants marketing authorizations in the EU. Final EC decisions customarily follow the CHMP's recommendation, and the companies expect to hear from the EC during the first quarter of 2008.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News